{"id":3806,"date":"2023-02-27T15:19:01","date_gmt":"2023-02-27T14:19:01","guid":{"rendered":"https:\/\/www.access2meds.eu\/startpagina\/"},"modified":"2025-06-24T09:59:50","modified_gmt":"2025-06-24T07:59:50","slug":"startpagina","status":"publish","type":"page","link":"https:\/\/www.access2meds.eu\/nl\/","title":{"rendered":"Startpagina"},"content":{"rendered":"

[et_pb_section fb_built=”1″ admin_label=”Header” _builder_version=”4.20.2″ _module_preset=”default” background_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1217229190_Nastasic.jpg” background_position=”top_center” height=”100vh” max_height=”660px” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.0″ _module_preset=”default” custom_padding=”7px|30px||30px|false|true” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” header_font=”|700|||||||” header_line_height=”1.1em” custom_margin=”11px||||false|false” global_colors_info=”{}”]<\/p>\n

VERBETERING VAN DE TOEGANG TOT<\/span>
INNOVATIEVE GEZONDHEIDSTECHNOLOGIE\u00cbN<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”first text blue pill” _builder_version=”4.20.0″ _module_preset=”default” background_enable_color=”off” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_row custom_padding_last_edited=”on|phone” module_class=”starttoppill” _builder_version=”4.20.2″ _module_preset=”default” background_color=”#3b3e84″ vertical_offset=”-90px” max_width=”1500px” module_alignment=”right” custom_margin=”||||false|false” custom_padding=”60px||50px|93px|false|false” custom_padding_tablet=”60px||50px|93px|false|false” custom_padding_phone=”|10px||65px|false|false” custom_css_main_element=”width:calc(100% – 125px)!important;” border_radii=”off|99999px|||99999px” global_colors_info=”{}” custom_css_main_element_last_edited=”on|phone” custom_css_main_element_phone=”width:calc(100%)!important;” custom_css_main_element_tablet=”width:calc(100% – 125px)!important;”][et_pb_column type=”4_4″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_font=”||||||||” text_text_color=”#FFFFFF” text_font_size=”24px” text_line_height=”1.33em” width=”100%” max_width=”825px” custom_margin_tablet=”” custom_margin_phone=”||0px||false|false” custom_margin_last_edited=”on|phone” custom_padding_tablet=”” custom_padding_phone=”||0px|10px|false|false” custom_padding_last_edited=”on|phone” text_font_size_tablet=”22px” text_font_size_phone=”16px” text_font_size_last_edited=”on|phone” text_line_height_tablet=”1.33em” text_line_height_phone=”1.2em” text_line_height_last_edited=”on|phone” global_colors_info=”{}”]<\/p>\n

ASCERTAIN (Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and ReimbursemenT models to Appraise INnovative health technologies) richt zich op de behoefte van pati\u00ebnten, artsen, betalers, regelgevers en fabrikanten om de betaalbaarheid en toegankelijkheid van innovatieve gezondheidstechnologie\u00ebn (waaronder geneesmiddelen) in Europa te verbeteren.<\/p>\n

[\/et_pb_text][et_pb_button button_url=”https:\/\/www.access2meds.eu\/nl\/impact\/” button_text=”Ontdek hoe jij hiervan kunt profiteren!” button_alignment=”right” module_class=”bubble-button” _builder_version=”4.20.2″ _module_preset=”default” custom_button=”on” button_text_size=”24px” button_text_color=”#FFFFFF” button_bg_color=”RGBA(255,255,255,0)” button_border_width=”0px” button_font=”||||||||” button_icon=”9||divi||400″ button_on_hover=”off” button_text_size_tablet=”24px” button_text_size_phone=”16px” button_text_size_last_edited=”on|phone” custom_css_main_element=”font-weight:500;” custom_css_after=”border-radius: 50%;background: #e85d6b;|| width: 30px;|| height: 30px;|| text-align: center; top:10px;|| line-height: 30px !important;” global_colors_info=”{}” custom_css_after_last_edited=”on|phone” custom_css_after_phone=”border-radius: 50%;background: #e85d6b;|| width: 20px;|| height: 20px;|| text-align: center; top:8px;|| line-height: 20px !important;” custom_css_after_tablet=”border-radius: 50%;background: #e85d6b;|| width: 30px;|| height: 30px;|| text-align: center; top:10px;|| line-height: 30px !important;”][\/et_pb_button][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”faq” module_id=”nagaan-faq” _builder_version=”4.20.2″ _module_preset=”default” overflow-x=”hidden” custom_padding=”0px||0px||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.0″ _module_preset=”default” custom_padding=”0px|30px||30px|false|true” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_font=”|600|||||||” text_font_size=”36px” header_font=”|600|||||||” header_text_align=”left” header_text_color=”#FFFFFF” header_font_size=”36px” header_line_height=”75px” background_color=”#e85d6b” background_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/fastforward.svg” background_size=”custom” background_image_width=”31px” background_image_height=”30px” background_position=”center_right” background_horizontal_offset=”27px” width=”160px” height=”75px” height_tablet=”75px” height_phone=”50px” height_last_edited=”on|phone” custom_padding=”|86px|||false|false” link_option_url=”https:\/\/www.access2meds.eu\/faq\/” header_font_size_tablet=”36px” header_font_size_phone=”24px” header_line_height_tablet=”75px” header_line_height_phone=”50px” header_line_height_last_edited=”on|phone” custom_css_main_element=”overflow:visible;” custom_css_after=”content:%22%22; display:block; width:2000px; height:100%; background:#e85d6b; position:absolute; top:0;right:160px;” border_radii=”off||9999px|9999px|” global_colors_info=”{}”]<\/p>\n

FAQ<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.20.0″ _module_preset=”default” background_color=”#fbedec” positioning=”absolute” position_origin_a=”top_center” vertical_offset=”408px” max_width=”100%” height=”675px” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_2,1_2″ _builder_version=”4.20.0″ _module_preset=”default” custom_padding=”|30px|60px|30px|false|true” global_colors_info=”{}”][et_pb_column type=”1_2″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_blurb title=”Wat is ASCERTAIN?” image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-542576580_sturti-1024×683.jpg” image_icon_width=”100%” _builder_version=”4.20.2″ _module_preset=”4d864e31-c790-4706-8bfe-634bfca688dd” global_colors_info=”{}”]<\/p>\n

ASCERTAIN is een project dat mensen moet helpen een betere toegang te krijgen tot nieuwe gezondheidstechnologie\u00ebn zoals medicijnen, medische apparatuur en tests. Het project ontwikkeltcre\u00ebert een tool dat kan worden gebruikt door beleidsmakers om inzicht te krijgen in de kosten en de waarde van deze nieuwe gezondheidstechnologie\u00ebn. <\/p>\n

[\/et_pb_blurb][et_pb_blurb title=”Wat houdt de ASCERTAIN beleidsondersteunende tool in?” image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1349268982-1024×683.jpg” image_icon_width=”100%” _builder_version=”4.20.2″ _module_preset=”4d864e31-c790-4706-8bfe-634bfca688dd” background_color=”#393C84″ custom_margin_tablet=”||0px||false|false” custom_margin_phone=”||0px||false|false” custom_margin_last_edited=”on|tablet” global_colors_info=”{}”]<\/p>\n

Het instrument zal voor iedereen toegankelijk zijn op het internet en informatie bevatten over de kosten en de waarde van deze nieuwe gezondheidstechnologie\u00ebn. Het zal ook rekening houden met de impact op het milieu. In het project wordt samengewerkt met pati\u00ebnten, de industrie, beleidsmakers en betalers om ervoor te zorgen dat de tool van goede kwaliteit en nuttig is. <\/p>\n

[\/et_pb_blurb][\/et_pb_column][et_pb_column type=”1_2″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}” custom_css_main_element_last_edited=”on|tablet” custom_css_main_element_tablet=”margin-bottom:0 !important;” custom_css_main_element_phone=”margin-bottom:0 !important;”][et_pb_blurb title=”Waarom is de betaalbaarheid van innovatieve gezondheidstechnologie\u00ebn een uitdaging?” image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1440000552-1024×683.jpg” _builder_version=”4.20.2″ _module_preset=”4d864e31-c790-4706-8bfe-634bfca688dd” background_color=”#E85D6B” custom_margin=”60px||30px||false|false” custom_margin_tablet=”0px||30px||false|false” custom_margin_phone=”0px||30px||false|false” custom_margin_last_edited=”on|tablet” global_colors_info=”{}”]<\/p>\n

Voor veel landen in de Europese Unie is het een uitdaging om zich nieuwe gezondheidstechnologie\u00ebn te veroorloven, omdat ze vaak duur zijn en niet iedereen er gelijke toegang toe heeft. Deze tool helpt besluitvormers te begrijpen hoeveel een technologie zou moeten kosten, wat de toegevoegde waarde ervan is voor pati\u00ebnten en wat de potenti\u00eble impact ervan is op het gezondheidszorgbudget. <\/p>\n

[\/et_pb_blurb][et_pb_blurb title=”Wat zijn de doelen van ASCERTAIN?” image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Foto_1132274611_iStock_PeopleImages-1024×653.jpg” _builder_version=”4.20.2″ _module_preset=”4d864e31-c790-4706-8bfe-634bfca688dd” background_color=”#86B8BD” custom_margin=”||||false|false” global_colors_info=”{}”]<\/p>\n

Het doel van ASCERTAIN is om het voor mensen makkelijker te maken om de kosten en de waarde van nieuwe gezondheidstechnologie\u00ebn te begrijpen. De tool zal voor iedereen toegankelijk zijn en kan worden aangepast aan de behoeften van verschillende landen. Het zal informatie bevatten over de kosten en de waarde van deze technologie\u00ebn en zal \u201cgroenere\u201d productie aanmoedigen. <\/p>\n

[\/et_pb_blurb][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ disabled_on=”on|on|off” module_id=”taal” _builder_version=”4.27.4″ _module_preset=”default” background_color=”rgba(134,184,189,0.3)” background_enable_image=”off” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”]<\/p>\n

WILT U DEZE PAGINA LIEVER IN EEN ANDERE TAAL LEZEN?<\/h3>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_4,1_4,1_4,1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/05\/Sprechblase_Englisch-1.png” title_text=”Engels” url=”https:\/\/www.access2meds.eu\/nl\/” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/06\/Sprechblase_Nederlands.png” title_text=”Nederlands” url=”https:\/\/www.access2meds.eu\/nl\/” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/05\/Sprechblase_Deutsch.png” title_text=”Sprachblase_Duits” url=”https:\/\/www.access2meds.eu\/de\/” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/05\/Sprechblase_France.png” title_text=”Frankrijk” url=”https:\/\/www.access2meds.eu\/fr\/” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/05\/Sprechblase_Romana.png” title_text=”Spreukblas_Romana” url=”https:\/\/www.access2meds.eu\/ro\/” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/06\/Sprechblase_Espanol.png” title_text=”Spreukblas_Espanol” url=”https:\/\/www.access2meds.eu\/es\/” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][et_pb_column type=”1_4″ _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/05\/Sprechblase_Norsk.png” title_text=”Spuitbus_Norsk” url=”https:\/\/www.access2meds.eu\/no\/” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2025\/05\/Sprechblase_Hrvatski.png” title_text=”Sprachblase_Hrvatski” url=”https:\/\/www.access2meds.eu\/hr\/” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_image][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”events” _builder_version=”4.27.4″ _module_preset=”default” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.0″ _module_preset=”default” custom_padding=”14px|30px|4px|30px|false|true” locked=”off” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.25.1″ _module_preset=”default” text_font=”|600|||||||” text_font_size=”36px” header_font=”|600||on|||||” header_text_align=”left” header_text_color=”#FFFFFF” header_font_size=”36px” header_line_height=”75px” background_color=”#393C84″ background_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/fastforward.svg” background_size=”custom” background_image_width=”31px” background_image_height=”30px” background_position=”center_right” background_horizontal_offset=”27px” width=”222px” height=”75px” height_tablet=”75px” height_phone=”50px” height_last_edited=”on|phone” custom_padding=”|60px|||false|false” link_option_url=”https:\/\/www.access2meds.eu\/news-events\/#ascertain-events” header_font_size_tablet=”36px” header_font_size_phone=”24px” header_line_height_tablet=”75px” header_line_height_phone=”50px” header_line_height_last_edited=”on|phone” custom_css_main_element=”overflow:visible;” custom_css_after=”content:%22%22; display:block; width:2000px; height:100%; background:#393c84; position:absolute; top:0;right:222px;” border_radii=”off||9999px|9999px|” global_colors_info=”{}”]<\/p>\n

Events<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.20.0″ _module_preset=”default” max_width=”1170px” custom_padding=”0px|0px||0px|false|true” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_code _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”]

\r\n\t
\r\n\t
\r\n\t
\r\n\t\t\t
\r\n\t\t\t\t21
-
21<\/span>\r\n\t\t\t\tokt<\/span>\r\n\t\t\t<\/div>\r\n\t<\/div>\r\n\t\r\n\t
\r\n\t\t
\r\n\t\t\t\r\n\t\t\r\n\t\t

ASCERTAIN Final Conference<\/a><\/h3>\r\n\r\n\t\t
\r\n\t\t\t

Join us in Brussels for our final ASCERTAIN conference.<\/p>\n\r\n\t\t\t\r\n\t\t<\/div>\r\n\t\t<\/div>\r\n\t\t

\r\n\t\t\t<\/a>\r\n\t\t\t\r\n\t\t<\/div>\r\n\t<\/div>\r\n<\/div>\t<\/div>\r\n<\/div>[\/et_pb_code][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”partnerlogos” module_id=”ascertain-news” _builder_version=”4.20.2″ _module_preset=”default” background_color=”#FFFFFF” custom_padding=”0px||0px||true|false” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.0″ _module_preset=”default” positioning=”absolute” position_origin_a=”top_center” custom_padding=”0px|30px|0px|30px|true|true” locked=”off” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.24.2″ _module_preset=”default” text_font=”|600|||||||” text_font_size=”36px” header_font=”|600|||||||” header_text_align=”left” header_text_color=”#FFFFFF” header_font_size=”36px” header_line_height=”75px” background_color=”#86B8BD” background_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/fastforward.svg” background_size=”custom” background_image_width=”31px” background_image_height=”30px” background_position=”center_right” background_horizontal_offset=”27px” width=”340px” width_tablet=”340px” width_phone=”250px” width_last_edited=”on|phone” height=”75px” height_tablet=”75px” height_phone=”50px” height_last_edited=”on|phone” custom_padding=”|86px|||false|false” link_option_url=”https:\/\/www.access2meds.eu\/nl\/consortium\/” header_font_size_tablet=”36px” header_font_size_phone=”24px” header_line_height_tablet=”75px” header_line_height_phone=”50px” header_line_height_last_edited=”on|phone” custom_css_main_element=”overflow:visible;” custom_css_after=”content:%22%22; display:block; width:2000px; height:100%; background:#048ea3; position:absolute; top:0;right:100%;” border_radii=”off||9999px|9999px|” global_colors_info=”{}”]<\/p>\n

VIDEO<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”news” module_id=”ascertain-news” _builder_version=”4.20.2″ _module_preset=”default” background_color=”#E85D6B” custom_padding=”0px||0px||true|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.2″ _module_preset=”default” positioning=”absolute” position_origin_a=”top_center” z_index=”100″ custom_padding=”0px|30px|0px|30px|true|true” locked=”off” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_font=”|600|||||||” text_font_size=”36px” header_font=”|600||on|||||” header_text_align=”left” header_text_color=”#FFFFFF” header_font_size=”36px” header_line_height=”75px” background_color=”#048EA3″ background_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/fastforward.svg” background_size=”custom” background_image_width=”31px” background_image_height=”30px” background_position=”center_right” background_horizontal_offset=”27px” width=”190px” height=”75px” height_tablet=”75px” height_phone=”50px” height_last_edited=”on|phone” custom_padding=”|60px|||false|false” link_option_url=”https:\/\/www.access2meds.eu\/news-events\/” header_font_size_tablet=”36px” header_font_size_phone=”24px” header_line_height_tablet=”75px” header_line_height_phone=”50px” header_line_height_last_edited=”on|phone” custom_css_main_element=”overflow:visible;” custom_css_after=”content:%22%22; display:block; width:2000px; height:100%; background:#048ea3; position:absolute; top:0;right:100%;” border_radii=”off||9999px|9999px|” global_colors_info=”{}”]<\/p>\n

News<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.20.0″ _module_preset=”default” max_width=”100%” module_alignment=”center” custom_padding=”0px|0px|0px||true|false” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_dp_dmb_module_205 _builder_version=”4.20.0″ _module_preset=”default” custom_padding=”|||30px|false|false” global_colors_info=”{}”][\/et_pb_dp_dmb_module_205][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ _builder_version=”4.27.4″ _module_preset=”default” background_enable_color=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” header_2_font=”|600||on|||||” max_width=”70%” module_alignment=”center” custom_margin=”||||false|false” locked=”off” global_colors_info=”{}”]<\/p>\n

Bekijk onze video’s voor meer informatie over het project<\/h2>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/www.youtube.com\/watch?v=JjYDG7BDNDE” _builder_version=”4.27.4″ _module_preset=”default” max_width=”70%” module_alignment=”center” global_colors_info=”{}”][\/et_pb_video][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” max_width=”70%” module_alignment=”center” custom_margin=”||||false|false” custom_padding=”10px||10px||false|false” global_colors_info=”{}”]<\/p>\n

Ontdek de totstandkoming van de zesdelige serie ‘3 Things About’. In zes video’s willen we complexe onderwerpen toegankelijker maken en een beter begrip kweken van de uitdagingen en kansen in onderwerpen rondom ASCERTAIN begrijpelijker te maken. <\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/www.youtube.com\/watch?v=6ZtwscRvEls” _builder_version=”4.27.4″ _module_preset=”default” max_width=”70%” module_alignment=”center” global_colors_info=”{}”][\/et_pb_video][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” max_width=”70%” module_alignment=”center” custom_margin=”||||false|false” custom_padding=”10px||10px||false|false” global_colors_info=”{}”]<\/p>\n

\u201c3 dingen over de waarde van nieuwe medicijnen tegen kanker\u201d – De zesde video in onze serie! Deze video onderzoekt hoe verschillende belanghebbenden de waarde van nieuwe geneesmiddelen tegen kanker defini\u00ebren. <\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/youtu.be\/xMF2ddO9abM” _builder_version=”4.27.4″ _module_preset=”default” max_width=”70%” module_alignment=”center” global_colors_info=”{}”][\/et_pb_video][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” max_width=”70%” module_alignment=”center” custom_margin=”||||false|false” custom_padding=”10px||10px||false|false” global_colors_info=”{}”]<\/p>\n

\u201c3 dingen over kosteneffectiviteit\u201d – De vijfde video in onze serie! Deze video gaat over kosteneffectiviteitsanalyse-een belangrijke methode om te beoordelen of behandelingen een goede prijs-kwaliteitverhouding hebben. <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/youtu.be\/e36OtJA90Qg” _builder_version=”4.27.4″ _module_preset=”default” max_width=”70%” module_alignment=”center” global_colors_info=”{}”][\/et_pb_video][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” max_width=”70%” module_alignment=”center” custom_margin=”||||false|false” custom_padding=”10px||10px||false|false” global_colors_info=”{}”]<\/p>\n

3 dingen over vergoedingen” is de vierde video in onze reeks. In deze video onderzoeken we de complexiteit van de terugbetaling van medicijnen – een belangrijke factor om de toegang van pati\u00ebnten tot nieuwe medicijnen te garanderen. <\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/www.youtube.com\/watch?v=6ZtwscRvEls” _builder_version=”4.27.4″ _module_preset=”default” max_width=”70%” module_alignment=”center” global_colors_info=”{}”][\/et_pb_video][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” max_width=”70%” module_alignment=”center” custom_margin=”||||false|false” custom_padding=”10px||10px||false|false” global_colors_info=”{}”]<\/p>\n

\u201c3 dingen over de prijs van nieuwe medicijnen\u201d – De derde video in onze serie! In deze video onderzoeken we de factoren die van invloed zijn op de prijs van medicijnen – een cruciaal onderwerp in de betaalbaarheid van de gezondheidszorg. <\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/www.youtube.com\/watch?v=OlmiWOpy6IA&t=2s” _builder_version=”4.27.4″ _module_preset=”default” max_width=”70%” module_alignment=”center” global_colors_info=”{}”][\/et_pb_video][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” max_width=”70%” module_alignment=”center” custom_margin=”||||false|false” custom_padding=”10px||10px||false|false” global_colors_info=”{}”]<\/p>\n

\u201c3 dingen over gedifferentieerde prijsbepaling\u201d – De tweede video in onze serie! In deze video leggen we het concept van gedifferentieerde prijsstelling uit – een strategie die wordt gebruikt om verschillende geneesmiddelenprijzen vast te stellen voor verschillende landen en pati\u00ebntengroepen. <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”1_3″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/youtu.be\/8NhuaohK_Qg” _builder_version=”4.27.4″ _module_preset=”default” max_width=”70%” module_alignment=”center” global_colors_info=”{}”][\/et_pb_video][et_pb_text _builder_version=”4.24.2″ _module_preset=”default” max_width=”70%” module_alignment=”center” custom_margin=”||||false|false” custom_padding=”10px||10px||false|false” global_colors_info=”{}”]<\/p>\n

\u201c3 dingen over markttoegang\u201d – De eerste video in onze serie! In deze video duiken we in het cruciale concept van markttoegang – een essentieel proces om nieuwe medicijnen en behandelingen beschikbaar te maken voor pati\u00ebnten. <\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/www.youtube.com\/watch?v=fvjJ4-2nOxk” _builder_version=”4.24.2″ _module_preset=”default” max_width=”70%” module_alignment=”center” global_colors_info=”{}”][\/et_pb_video][et_pb_text _builder_version=”4.24.2″ _module_preset=”default” max_width=”70%” module_alignment=”center” custom_margin=”||||false|false” custom_padding=”10px||10px||false|false” global_colors_info=”{}”]<\/p>\n

Ontdek hoe ASCERTAIN ongelijkheden in de toegang tot gezondheidszorgtechnologie\u00ebn aanpakt met onze nieuwste animatievideo! Lees meer over de missie van het project om de betaalbaarheid en duurzaamheid te verbeteren en tegelijkertijd innovatie te bevorderen en rekening te houden met de gevolgen voor het milieu. <\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.24.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_video src=”https:\/\/youtu.be\/sbPnTmX8Uxs” _builder_version=”4.27.4″ _module_preset=”default” max_width=”70%” module_alignment=”center” global_colors_info=”{}”][\/et_pb_video][et_pb_text _builder_version=”4.27.4″ _module_preset=”default” max_width=”70%” module_alignment=”center” custom_margin=”||||false|false” custom_padding=”10px||10px||false|false” global_colors_info=”{}”]<\/p>\n

Met veel plezier delen we onze video over de lancering van het ASCERTAIN project in Rotterdam! Onze consortiumleden kwamen bijeen om de aftrap te geven voor dit door HORIZON gefinancierde project. <\/span><\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ module_id=”neem contact op met” _builder_version=”4.20.2″ _module_preset=”default” background_color=”#86B8BD” custom_margin=”||||false|false” custom_padding=”16px||75px||false|false” box_shadow_style=”preset7″ box_shadow_horizontal=”0px” box_shadow_vertical=”-274px” box_shadow_color=”#FFFFFF” global_module=”910″ saved_tabs=”all” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” header_font=”Poppins semibold|||on|||||” header_font_size=”36px” custom_margin=”14px||23px||false|false” custom_margin_tablet=”” custom_margin_phone=”||30px||false|false” custom_margin_last_edited=”on|phone” header_font_size_phone=”24px” global_colors_info=”{}”]<\/p>\n

Contact<\/h1>\n

[\/et_pb_text][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_font=”Poppins regular||||||||” text_text_color=”#393C84″ text_font_size=”24px” text_line_height=”1.33em” module_alignment=”right” custom_margin=”||0px||false|false” text_font_size_tablet=”” text_font_size_phone=”18px” text_font_size_last_edited=”on|phone” global_colors_info=”{}”]<\/p>\n

Neem contact met ons op als je vragen of opmerkingen hebt! We nemen zo snel mogelijk contact met je op. <\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row column_structure=”1_3,1_3,1_3″ use_custom_gutter=”on” module_class=”tablet-three-cols” _builder_version=”4.20.2″ _module_preset=”default” max_width_tablet=”980px” max_width_phone=”500px” max_width_last_edited=”on|phone” custom_padding=”0px|30px|0px|30px|false|true” global_colors_info=”{}” custom_css_main_element_last_edited=”on|phone” custom_css_main_element_tablet=”display:flex;” custom_css_main_element_phone=”display:flex; flex-direction:column;”][et_pb_column type=”1_3″ _builder_version=”4.20.2″ _module_preset=”be0fba28-f74a-4ba0-9a8d-9cd30aca805d” global_colors_info=”{}” custom_css_main_element_last_edited=”on|tablet” custom_css_main_element_tablet=”margin-bottom:0;” custom_css_main_element_phone=”margin-bottom:20px;”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Carin_Uyl-de-Groot.png” title_text=”Carin_Uyl-de-Groot” _builder_version=”4.20.2″ _module_preset=”a348f9e0-d57b-4c22-b522-c52b784fe57f” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_text_color=”#FFFFFF” link_text_color=”#FFFFFF” global_colors_info=”{}”]<\/p>\n

Voor onderzoeksgerelateerde vragen:<\/p>\n

Carin Uyl-de Groot<\/strong>
Projectco\u00f6rdinator<\/p>\n

Erasmus Universiteit Rotterdam
uyl@eshpm.eur.nl<\/a>
Telefoon: +31 10 4081583<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.20.2″ _module_preset=”be0fba28-f74a-4ba0-9a8d-9cd30aca805d” background_color=”#393C84″ global_colors_info=”{}” custom_css_main_element_last_edited=”on|phone” custom_css_main_element_tablet=”margin-bottom:0;” custom_css_main_element_phone=”margin-bottom:20px;”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Marcel-Langone-1.png” title_text=”Marcel-Langone” align=”center” _builder_version=”4.20.2″ _module_preset=”a348f9e0-d57b-4c22-b522-c52b784fe57f” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_text_color=”#FFFFFF” link_text_color=”#FFFFFF” global_colors_info=”{}”]<\/p>\n

Voor algemene projectvragen:<\/p>\n

Marcel Langone Marques<\/strong>
Projectmanager<\/p>\n

Erasmus Universiteit Rotterdam
marcel.langonemarques@eur.nl<\/a>
Telefoon: +31 10 4081583<\/p>\n

[\/et_pb_text][\/et_pb_column][et_pb_column type=”1_3″ _builder_version=”4.20.2″ _module_preset=”be0fba28-f74a-4ba0-9a8d-9cd30aca805d” background_color=”#048EA3″ global_colors_info=”{}”][et_pb_image src=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/06\/My-project-1-7.png” title_text=”Mijn project-1 (7)” _builder_version=”4.21.0″ _module_preset=”a348f9e0-d57b-4c22-b522-c52b784fe57f” global_colors_info=”{}”][\/et_pb_image][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_text_color=”#FFFFFF” link_text_color=”#FFFFFF” global_colors_info=”{}”]<\/p>\n

Voor communicatie:<\/p>\n

Lena Jessen<\/strong>
Projectmanager<\/p>\n

OptiMedis
l.jessen@optimedis.de<\/a>
Telefoon: +49 40 226211490<\/p>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section][et_pb_section fb_built=”1″ admin_label=”partnerlogos” module_id=”ascertain-news” _builder_version=”4.20.2″ _module_preset=”default” background_color=”#FFFFFF” custom_padding=”0px||0px||true|false” locked=”off” global_colors_info=”{}”][et_pb_row _builder_version=”4.20.0″ _module_preset=”default” positioning=”absolute” position_origin_a=”top_center” custom_padding=”0px|30px|0px|30px|true|true” locked=”off” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_text _builder_version=”4.20.2″ _module_preset=”default” text_font=”|600|||||||” text_font_size=”36px” header_font=”|600|||||||” header_text_align=”left” header_text_color=”#FFFFFF” header_font_size=”36px” header_line_height=”75px” background_color=”#048EA3″ background_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/fastforward.svg” background_size=”custom” background_image_width=”31px” background_image_height=”30px” background_position=”center_right” background_horizontal_offset=”27px” width=”340px” width_tablet=”340px” width_phone=”250px” width_last_edited=”on|phone” height=”75px” height_tablet=”75px” height_phone=”50px” height_last_edited=”on|phone” custom_padding=”|86px|||false|false” link_option_url=”https:\/\/www.access2meds.eu\/nl\/consortium\/” header_font_size_tablet=”36px” header_font_size_phone=”24px” header_line_height_tablet=”75px” header_line_height_phone=”50px” header_line_height_last_edited=”on|phone” custom_css_main_element=”overflow:visible;” custom_css_after=”content:%22%22; display:block; width:2000px; height:100%; background:#048ea3; position:absolute; top:0;right:100%;” border_radii=”off||9999px|9999px|” global_colors_info=”{}”]<\/p>\n

Partners<\/h1>\n

[\/et_pb_text][\/et_pb_column][\/et_pb_row][et_pb_row _builder_version=”4.20.2″ _module_preset=”default” module_alignment=”center” custom_padding=”90px|30px|0px|30px|false|true” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.20.0″ _module_preset=”default” global_colors_info=”{}”][et_pb_dp_oc_custom show_arrow=”off” show_control=”off” thumbnail_size=”medium_large” number_thumb=”4″ number_thumb_tablet=”4″ number_thumb_phone=”2″ number_thumb_last_edited=”on|phone” item_margin=”20″ _builder_version=”4.27.4″ _module_preset=”default” custom_padding=”30px||135px||false|false” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″][et_pb_dp_oc_custom_item upload_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Chino.io-logo-1.png” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-chino-srl\/” admin_title=”CINO.IO” _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/EUR-endorsement_01_RGB_2400_colour.png” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-erasmus-universiteit-rotterdam\/” admin_title=”EUR” _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/MPE-Logo-1.png” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-myeloma-patients-europe-aisbl\/” admin_title=”MP” _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/Comenius_University_Bratislava-1.svg” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-comenius-university-bratislava\/” admin_title=”CUB” _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/R.png” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-universitetet-i-oslo\/” admin_title=”UiO” _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/06\/wortbildmarke-goeg-RGB.png” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-gesundheit-osterreich-gmbh\/” admin_title=”G\u00d6” _builder_version=”4.25.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2024\/08\/Logo-EHA-Black.png” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-european-hematology-association\/” admin_title=”EHA” _builder_version=”4.27.0″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/AIM-LOGO_png24-1.png” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-association-internationale-de-la-mutualite-aim\/” admin_title=”AIM” _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_dp_oc_custom_item][et_pb_dp_oc_custom_item upload_image=”https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/OptiMedis_RGB.svg” url=”https:\/\/www.access2meds.eu\/consortium\/team-members-optimedis-ag\/” admin_title=”optimedis” _builder_version=”4.20.2″ _module_preset=”default” global_colors_info=”{}”][\/et_pb_dp_oc_custom_item][\/et_pb_dp_oc_custom][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"

ASCERTAIN richt zich op de behoefte van pati\u00ebnten, artsen, betalers, regelgevers en fabrikanten om de betaalbaarheid en toegankelijkheid van innovatieve gezondheidstechnologie\u00ebn (waaronder geneesmiddelen) in Europa te verbeteren.<\/p>\n","protected":false},"author":1,"featured_media":3808,"parent":0,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"class_list":["post-3806","page","type-page","status-publish","has-post-thumbnail","hentry"],"yoast_head":"\nASCERTAIN - DE TOEGANG TOT INNOVATIEVE GEZONDHEIDSTECHNOLOGIE\u00cbN VERBETEREN<\/title>\n<meta name=\"description\" content=\"ASCERTAIN voorziet in de behoefte van pati\u00ebnten, artsen, betalers, regelgevers en fabrikanten om de betaalbaarheid en toegankelijkheid van innovatieve gezondheidstechnologie\u00ebn (waaronder geneesmiddelen) in Europa te verbeteren.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.access2meds.eu\/nl\/startpagina\/\" \/>\n<meta property=\"og:locale\" content=\"nl_NL\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"ZEKERHEID - VERBETERING VAN DE TOEGANG TOT INNOVATIEVE GEZONDHEIDSTECHNOLOGIE\u00cbN\" \/>\n<meta property=\"og:description\" content=\"ASCERTAIN voorziet in de behoefte van pati\u00ebnten, artsen, betalers, regelgevers en fabrikanten om de betaalbaarheid en toegankelijkheid van innovatieve gezondheidstechnologie\u00ebn (waaronder geneesmiddelen) in Europa te verbeteren.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.access2meds.eu\/nl\/startpagina\/\" \/>\n<meta property=\"og:site_name\" content=\"ASCERTAIN\" \/>\n<meta property=\"article:modified_time\" content=\"2025-06-24T07:59:50+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/Social_ASCERTAIN.png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:title\" content=\"ZEKERHEID - VERBETERING VAN DE TOEGANG TOT INNOVATIEVE GEZONDHEIDSTECHNOLOGIE\u00cbN\" \/>\n<meta name=\"twitter:description\" content=\"ASCERTAIN voorziet in de behoefte van pati\u00ebnten, artsen, betalers, regelgevers en fabrikanten om de betaalbaarheid en toegankelijkheid van innovatieve gezondheidstechnologie\u00ebn (waaronder geneesmiddelen) in Europa te verbeteren.\" \/>\n<meta name=\"twitter:image\" content=\"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/Social_ASCERTAIN.png\" \/>\n<meta name=\"twitter:site\" content=\"@ASCERTAIN_EU\" \/>\n<meta name=\"twitter:label1\" content=\"Geschatte leestijd\" \/>\n\t<meta name=\"twitter:data1\" content=\"25 minuten\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/startpagina\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/startpagina\\\/\",\"name\":\"ASCERTAIN - DE TOEGANG TOT INNOVATIEVE GEZONDHEIDSTECHNOLOGIE\u00cbN VERBETEREN\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/startpagina\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/startpagina\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/iStock-1217229190_Nastasic.jpg\",\"datePublished\":\"2023-02-27T14:19:01+00:00\",\"dateModified\":\"2025-06-24T07:59:50+00:00\",\"description\":\"ASCERTAIN voorziet in de behoefte van pati\u00ebnten, artsen, betalers, regelgevers en fabrikanten om de betaalbaarheid en toegankelijkheid van innovatieve gezondheidstechnologie\u00ebn (waaronder geneesmiddelen) in Europa te verbeteren.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/startpagina\\\/#breadcrumb\"},\"inLanguage\":\"nl-NL\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/startpagina\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/startpagina\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/iStock-1217229190_Nastasic.jpg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/03\\\/iStock-1217229190_Nastasic.jpg\",\"width\":1900,\"height\":1267},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/startpagina\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Startseite\",\"item\":\"https:\\\/\\\/www.access2meds.eu\\\/nl\\\/startpagina\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Startpagina\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#website\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"name\":\"ASCERTAIN\",\"description\":\"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.access2meds.eu\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"nl-NL\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#organization\",\"name\":\"ASCERTAIN\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"nl-NL\",\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"contentUrl\":\"https:\\\/\\\/www.access2meds.eu\\\/wp-content\\\/uploads\\\/2023\\\/02\\\/ASCERTAIN-logo.svg\",\"width\":1,\"height\":1,\"caption\":\"ASCERTAIN\"},\"image\":{\"@id\":\"https:\\\/\\\/www.access2meds.eu\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/ASCERTAIN_EU\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/ascertain-eu\\\/\",\"https:\\\/\\\/www.youtube.com\\\/@ascertainproject\"]}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"ASCERTAIN - DE TOEGANG TOT INNOVATIEVE GEZONDHEIDSTECHNOLOGIE\u00cbN VERBETEREN","description":"ASCERTAIN voorziet in de behoefte van pati\u00ebnten, artsen, betalers, regelgevers en fabrikanten om de betaalbaarheid en toegankelijkheid van innovatieve gezondheidstechnologie\u00ebn (waaronder geneesmiddelen) in Europa te verbeteren.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.access2meds.eu\/nl\/startpagina\/","og_locale":"nl_NL","og_type":"article","og_title":"ZEKERHEID - VERBETERING VAN DE TOEGANG TOT INNOVATIEVE GEZONDHEIDSTECHNOLOGIE\u00cbN","og_description":"ASCERTAIN voorziet in de behoefte van pati\u00ebnten, artsen, betalers, regelgevers en fabrikanten om de betaalbaarheid en toegankelijkheid van innovatieve gezondheidstechnologie\u00ebn (waaronder geneesmiddelen) in Europa te verbeteren.","og_url":"https:\/\/www.access2meds.eu\/nl\/startpagina\/","og_site_name":"ASCERTAIN","article_modified_time":"2025-06-24T07:59:50+00:00","og_image":[{"url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/Social_ASCERTAIN.png","type":"","width":"","height":""}],"twitter_card":"summary_large_image","twitter_title":"ZEKERHEID - VERBETERING VAN DE TOEGANG TOT INNOVATIEVE GEZONDHEIDSTECHNOLOGIE\u00cbN","twitter_description":"ASCERTAIN voorziet in de behoefte van pati\u00ebnten, artsen, betalers, regelgevers en fabrikanten om de betaalbaarheid en toegankelijkheid van innovatieve gezondheidstechnologie\u00ebn (waaronder geneesmiddelen) in Europa te verbeteren.","twitter_image":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/04\/Social_ASCERTAIN.png","twitter_site":"@ASCERTAIN_EU","twitter_misc":{"Geschatte leestijd":"25 minuten"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/www.access2meds.eu\/nl\/startpagina\/","url":"https:\/\/www.access2meds.eu\/nl\/startpagina\/","name":"ASCERTAIN - DE TOEGANG TOT INNOVATIEVE GEZONDHEIDSTECHNOLOGIE\u00cbN VERBETEREN","isPartOf":{"@id":"https:\/\/www.access2meds.eu\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.access2meds.eu\/nl\/startpagina\/#primaryimage"},"image":{"@id":"https:\/\/www.access2meds.eu\/nl\/startpagina\/#primaryimage"},"thumbnailUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1217229190_Nastasic.jpg","datePublished":"2023-02-27T14:19:01+00:00","dateModified":"2025-06-24T07:59:50+00:00","description":"ASCERTAIN voorziet in de behoefte van pati\u00ebnten, artsen, betalers, regelgevers en fabrikanten om de betaalbaarheid en toegankelijkheid van innovatieve gezondheidstechnologie\u00ebn (waaronder geneesmiddelen) in Europa te verbeteren.","breadcrumb":{"@id":"https:\/\/www.access2meds.eu\/nl\/startpagina\/#breadcrumb"},"inLanguage":"nl-NL","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.access2meds.eu\/nl\/startpagina\/"]}]},{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.access2meds.eu\/nl\/startpagina\/#primaryimage","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1217229190_Nastasic.jpg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/03\/iStock-1217229190_Nastasic.jpg","width":1900,"height":1267},{"@type":"BreadcrumbList","@id":"https:\/\/www.access2meds.eu\/nl\/startpagina\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Startseite","item":"https:\/\/www.access2meds.eu\/nl\/startpagina\/"},{"@type":"ListItem","position":2,"name":"Startpagina"}]},{"@type":"WebSite","@id":"https:\/\/www.access2meds.eu\/#website","url":"https:\/\/www.access2meds.eu\/","name":"ASCERTAIN","description":"IMPROVING ACCESS TO INNOVATIVE HEALTH TECHNOLOGIES","publisher":{"@id":"https:\/\/www.access2meds.eu\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.access2meds.eu\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"nl-NL"},{"@type":"Organization","@id":"https:\/\/www.access2meds.eu\/#organization","name":"ASCERTAIN","url":"https:\/\/www.access2meds.eu\/","logo":{"@type":"ImageObject","inLanguage":"nl-NL","@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/","url":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","contentUrl":"https:\/\/www.access2meds.eu\/wp-content\/uploads\/2023\/02\/ASCERTAIN-logo.svg","width":1,"height":1,"caption":"ASCERTAIN"},"image":{"@id":"https:\/\/www.access2meds.eu\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/ASCERTAIN_EU","https:\/\/www.linkedin.com\/company\/ascertain-eu\/","https:\/\/www.youtube.com\/@ascertainproject"]}]}},"_links":{"self":[{"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/pages\/3806","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/comments?post=3806"}],"version-history":[{"count":20,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/pages\/3806\/revisions"}],"predecessor-version":[{"id":4502,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/pages\/3806\/revisions\/4502"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/media\/3808"}],"wp:attachment":[{"href":"https:\/\/www.access2meds.eu\/nl\/wp-json\/wp\/v2\/media?parent=3806"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}